H.C. Wainwright raised the firm’s price target on Xeris Biopharma (XERS) to $6.60 from $6 and keeps a Buy rating on the shares. The company reported a big Q3 beat excluding GAAP non-cash items as its growth assets are outperforming, the analyst tells investors in a research note.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.